The kidney - The body's playground for drugs: An overview of renal drug handling with selected clinical correlates

Canadian Journal of Clinical Pharmacology

Volumn 10, Issue 1, 2003, Pages 17-23

  Perri, Dan ^a,b,e   Ito, Shinya ^c   Rowsell, Victoria ^d   Shear, Neil H ^b  

^a MCMASTER UNIVERSITY   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

Drug transport; Kidney; P glycoprotein; Renal drug handling; Transport protein

Indexed keywords

AMPHOTERICIN B; CARRIER PROTEIN; CEPHALOSPORIN DERIVATIVE; CIMETIDINE; DIGOXIN; GLYCOPROTEIN P; HISTAMINE H2 RECEPTOR ANTAGONIST; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLIN G; PROBENECID; PROCAINAMIDE; QUINIDINE; SALICYLIC ACID; SULFINPYRAZONE; THIAZIDE DIURETIC AGENT; TRIAMTERENE; TRIMETHOPRIM;

BASOLATERAL MEMBRANE; BRUSH BORDER; DRUG METABOLISM; DRUG SAFETY; DRUG TRANSPORT; GLOMERULUS FILTRATION RATE; HUMAN; HYDROPHOBICITY; KIDNEY CLEARANCE; KIDNEY FUNCTION; KIDNEY TUBULE ABSORPTION; KIDNEY TUBULE CELL; KIDNEY TUBULE EXCRETION; MOLECULAR BIOLOGY; MULTIDRUG RESISTANCE; REVIEW; URINARY EXCRETION;

EID: 0038586446     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (46)

1. Luke DR, Halstenson CE, Opsahl JA, et al. Validity of creatinine clearance estimates in the assessment of renal function. Clin Pharmacol Ther 1990;48:503-8.
2. Paap CM, Nahata MC. Prospective evaluation of ten methods for estimating creatinine clearance in pediatric patients with varying degrees of renal dysfunction. Pharmacotherapy 1991;11:271.
3. Schwartz GJ, Feld LG, Langford DJ. A simple estimate of glomerular filtration rate in full-term infants during the first year of life. J Pediatr 1984;104:849-54.
4. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999;130:461-70.
5. Ito S. Drug secretion systems in renal tubular cells: functional models and molecular identity. Pediatr Nephrol 1999;13:980-8.
6. Inui K, Masuda S, Saito H. Cellular and molecular aspects of drug transport in the kidney. Kidney Int 2000;58:944-58.
7. Gorboulev V, Ulzherimer JC, Akhoundova A, et al. Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol 1997;16:871-81.
8. Tamia I, Yabuuchi H, Nezu J, et al. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS 1997;419:107-11. (Lett)
9. Gros P, Neriah YP, Croop JM, Housman D. Isolation and expression of a cDNA that confers multidrug resistance. Nature 1986;323: 728-31.
10. Kullak-Ublick GA, Hagenbuch B, Steiger B, et al. Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology 1995;109:1274-82.
11. +)-dependent purine nucleoside transporter from human kidney: Cloning and functional characterization. Am J Physiol 1997;273:F1058-F1065.
12. Van Aubel RA, Masereeuw R, Russel FG. Molecular pharmacology of renal organic anion transporters. Am J Physiol Renal Physiol 2000;279:F216-F232.
13. Lu R, Kanai N, Bao Y, Schuster VL. Cloning, in vitro expression, and tissue distribution of a human prostaglandin transporter cDNA (hPGT). J Clin Invest 1996;98:1142-9.
14. Cole SPC, Bhardwaj G, Gerlach JH, et al. Overexpression of a novel transporter gene in a multidrug resistant human lung cancer cell line. Science 1992;258:1650-4.
15. Evers R, Kool M, van Deemter L, et al. Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA. J Clin Invest 1998;101:1310-9.
16. Ishikawa T. The ATP-dependent glutathione S-conjugate export pump. Trends Biochem Sci 1992;17:463-8.
17. Sekine T, Watanabe N, Hosoyamada, et al. Expression, cloning, and characterization of a novel multispecific organic anion transporter. J Biol Chem 1997;272:18526-9.
18. Sweet DH, Wolff NA, Pritchard JB. Expression, cloning, and characterization of ROAT1. J Biol Chem 1997;272:30088-95.
19. Race JE, Grassl SM, Williams WJ, Holtzman EJ. Molecular cloning and characterization of two novel human renal organic anion transporters hOAT1 and hOAT3. Biochem Biophys Res Commun 1999;255:508-14.
20. Reid G, Wolff NA, Dautzenberg FM, Burckhardt G. Cloning of the human renal p-aminohippurate transporter, hROAT1. Kidney Blood Press Res 1998;21:233-7.
21. Kool M, de Haas M, Scheffer GI, et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 1997;57:3537-47.
22. Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a p-glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995;96:1698-1705.
23. +-nucleoside cotransporter (hCNT1). Am J Physiol 1997;272:C707-14.
24. +dependent nucleoside transporter (hSPNT1) in a mammalian expression system. J Pharmacol Exp Ther 1999;289:1487-91.
25. +/nucleoside cotransporter (hCNT2) selective for purine nucleosides and uridine. Mol Membr Biol 1998;15:203-11.
26. Masuda S, Saito H, Inui K. Interactions of nonsteroidal antiinflammatory drugs with rat renal organic anion transporter, OAT-K1. J Pharmacol Exp Ther 1997;283:1039-42.
27. Schuetz JD, Connelly MC, Sun D, et al. MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med 1999;5:1048-51.
28. Chen R, Pan BF, Sakurai M, Nelson JA. A nucleoside-sensitive organic cation transporter in opossum kidney cells. Am J Physiol 1999;276:F323-F328.
29. Chen R, Nelson JA. Role of organic cation transporters in the renal secretion of nucleosides. Biochem Pharmacol 2000;60:215-9.
30. Zhang L, Gorset W, Washington CB, et al. Interactions of HIV protease inhibitors with a human organic cation transporter in a mammalian expression system. Drug Metab Dispos 2000;28:329-34.
31. Shapiro AB, Ling V. The mechanism of ATP-dependent multidrug transport by P-glycoprotein. Acta Physiologica Scandinavica 1998;643:227-34.
32. Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): Possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol 1998;56:733-42.
33. Washington CB, Duran GE, Man MC, et al. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. JAIDS 1998;19:203-9.
34. Rebbeor JF, Senior AE. Effects of cardiovascular drugs on ATPase activity of P-glycoprotein in plasma membranes and in purified reconstituted form. Biochimica Biophysica Acta 1998;1369:85-93.
35. Fromm MF, Kim RB, Stein CM, et al. Inhibition of P-glycoproteinmediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999;99:552-7.
36. Ito S, Woodland C, Harper PA, Koren G. The mechanism of the verapamil-digoxin interaction in renal tubular cells (LLC-PK1). Life Sciences 1993;53:PL399-403.
37. Wakasugi H, Yano I, Ito T, et al. Effect of clarithromycin on renal excretion of digoxin: Interaction with P-glycoprotein. Clin Pharmacol Ther 1998;64:123-8.
38. Woodland C, Verjee Z, Giesbrecht E, et al. The digoxinpropafenone interaction: Characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther 1997;283:39-45.
39. Okamura N, Hirai M, Tanigawara Y, et al. Digoxin-cyclosporin A interaction: Modulation of the multidrug transporter P-glycoprotein in the kidney. J Pharmacol Exp Ther 1993;266:1614-9.
40. Lum BL, Kaubisch S, Yahanda AM, et al. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance. J Clin Oncol 1992;10:1635-42.
41. Hebert MF, Lam AY. Diltiazem increases tacrotimus concentrations. Ann Pharmacother 1999;33:360-2.
42. Hebert MF, Fisher RM, Marsh CL, et al. Effects of rifampin on tacrolimus pharmacokinetics in healthy volunteers. J Clin Pharmacol 1999;39:91-6.
43. Tramonti G, Romiti N, Norpoth M, Chieli E. P-glycoprotein in HK-2 proximal tubule cell line. Ren Fail 2001;23:331-7
44. Takanaga H, Ohnishi A, Matsuo H, Sawada Y. Inhibition of vinblastin efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 2001;21:1062-6.
45. Wang EJ, Casciano CN, Clement RP, Johnson WW. Inhibition of P-glycoprotein transport function by grapefruit juice psoralen. Pharm Res 2001;18:432-8.
46. Laouari D, Yang R, Veau C, Blanke I, Friedlander G. Two apical multidrug transporters, P-gp and MRP2, are differently altered in chronic renal failure. Am J Physiol Renal Physiol 2001;280:F636-F645.